[go: up one dir, main page]

PE20030311A1 - Composicion oftalmica que comprende ascomicina - Google Patents

Composicion oftalmica que comprende ascomicina

Info

Publication number
PE20030311A1
PE20030311A1 PE2002000808A PE2002000808A PE20030311A1 PE 20030311 A1 PE20030311 A1 PE 20030311A1 PE 2002000808 A PE2002000808 A PE 2002000808A PE 2002000808 A PE2002000808 A PE 2002000808A PE 20030311 A1 PE20030311 A1 PE 20030311A1
Authority
PE
Peru
Prior art keywords
copolymer
ascomycin
composition including
ophthalmic composition
eye
Prior art date
Application number
PE2002000808A
Other languages
English (en)
Inventor
Jean-Claude Bizec
Andrea Fetz
Christian Schoch
Kasey Jon Minick
Michelle Pik-Han Wong
Maggy Babiole Saunier
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23219986&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20030311(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20030311A1 publication Critical patent/PE20030311A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

QUE COMPRENDE: 1)33-EPI-CLORO-33-DESOXI-ASCOMICINA.; 2)AL MENOS UN POLIMERO SELECCIONADO DE: i)UN COPOLIMERO O COPOLIMERO DE BLOQUE DE POLIOXIETILENO-POLIOXIPROPILENO; Y, ii)UN HOMO- o COPOLIMERO RETICULADO DE ACIDO ACRILICO; 3)UN AGENTE MEJORADOR DE TONICIDAD; UN REGULADOR DE PH, UN CONSERVADOR Y UN VEHICULO OFTALMICO. TIENE APLICACION EN EL TRATAMIENTO DE CONDICIONES INMUNO-MEDIADAS DEL OJO, TALES COMO ENFERMEDADES AUTOINMUNES, COMO OJO RESECO, UVEITIS, QUERATOPLASTIA O QUERATITIS CRONICA, CONDICIONES ALERGICAS COMO CONJUNTIVITIS VERNAL, CONDICIONES INFLAMATORIAS O TRANSPLANTE DE CORNEA
PE2002000808A 2001-08-23 2002-08-22 Composicion oftalmica que comprende ascomicina PE20030311A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31444801P 2001-08-23 2001-08-23

Publications (1)

Publication Number Publication Date
PE20030311A1 true PE20030311A1 (es) 2003-05-08

Family

ID=23219986

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000808A PE20030311A1 (es) 2001-08-23 2002-08-22 Composicion oftalmica que comprende ascomicina

Country Status (27)

Country Link
US (2) US20030050255A1 (es)
EP (1) EP1420787B8 (es)
JP (1) JP2005501105A (es)
KR (2) KR20100089108A (es)
CN (1) CN100366251C (es)
AR (1) AR035293A1 (es)
AT (1) ATE452638T1 (es)
AU (1) AU2002331172B2 (es)
BR (1) BR0211972A (es)
CA (1) CA2457034C (es)
CO (1) CO5560568A2 (es)
DE (1) DE60234840D1 (es)
EC (1) ECSP044981A (es)
ES (1) ES2337130T3 (es)
HU (1) HUP0402396A3 (es)
IL (1) IL160374A0 (es)
MX (1) MXPA04001646A (es)
MY (1) MY157377A (es)
NO (1) NO20040775L (es)
NZ (1) NZ531224A (es)
PE (1) PE20030311A1 (es)
PL (1) PL208685B1 (es)
PT (1) PT1420787E (es)
RU (1) RU2313344C2 (es)
TW (1) TWI324925B (es)
WO (1) WO2003017990A2 (es)
ZA (1) ZA200400772B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
BE1015610A3 (nl) * 2003-07-17 2005-06-07 Corrutech Nv Verbeterde lijm en werkwijze voor het vervaardigen ervan.
US7083802B2 (en) * 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
AU2004274026A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US8637070B2 (en) 2005-02-09 2014-01-28 Santen Pharmaceutical Co., Ltd. Rapamycin formulations and methods of their use
AU2006270041B2 (en) 2005-07-18 2011-08-18 Minu, Llc Enhanced ocular neuroprotection/neurostimulation
EP2001438A2 (en) 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
BRPI0709016A2 (pt) 2006-03-23 2011-06-21 Macusight Inc formulações e métodos para doenças ou condições relacionadas com a permeabilidade vascular
US8541426B2 (en) * 2007-07-11 2013-09-24 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
BRPI0910850B1 (pt) 2008-04-21 2022-06-14 Otonomy, Inc. Composição intratimpânica compreendendo fator neurotrófico de crescimento derivado do cérebro (bdnf) para o tratamento ou prevenção da perda auditiva
CN102026623B (zh) 2008-05-14 2013-08-14 奥德纳米有限公司 用于治疗耳部病症的控制释放皮质类固醇组合物和方法
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US8349353B2 (en) 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
WO2010011605A2 (en) 2008-07-21 2010-01-28 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
AU2009307825A1 (en) 2008-10-22 2010-04-29 Rick FRIEDMAN Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
AU2014311358A1 (en) 2013-08-27 2016-04-07 Otonomy, Inc. Treatment of pediatric otic disorders
CA3004849C (en) 2015-11-16 2024-06-11 Georges Gaudriault A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
WO2018053173A1 (en) 2016-09-16 2018-03-22 Otonomy, Inc. Otic gel formulations for treating otitis externa
JP7699426B2 (ja) * 2018-11-30 2025-06-27 ロート製薬株式会社 光線による障害からの細胞保護用眼科組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2084722T3 (es) * 1990-05-29 1996-05-16 Boston Ocular Res Composicion para tratamiento del ojo seco.
US5247076A (en) * 1991-09-09 1993-09-21 Merck & Co., Inc. Imidazolidyl macrolides having immunosuppressive activity
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
JPH06345646A (ja) * 1993-06-08 1994-12-20 Fujisawa Pharmaceut Co Ltd ローション剤
CZ289773B6 (cs) * 1994-10-26 2002-04-17 Novartis Ag Farmaceutický prostředek pro místní aplikaci
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
CN1259053A (zh) * 1997-04-11 2000-07-05 藤泽药品工业株式会社 药物组合物
CZ287497B6 (cs) * 1997-12-30 2000-12-13 Galena, A. S. Topické oční přípravky s imunosupresivními látkami
CA2372448A1 (en) * 1999-04-30 2000-11-09 Sucampo Ag Use of macrolide compounds for the treatment of dry eye

Also Published As

Publication number Publication date
US20110071186A1 (en) 2011-03-24
IL160374A0 (en) 2004-07-25
CA2457034A1 (en) 2003-03-06
EP1420787B1 (en) 2009-12-23
AR035293A1 (es) 2004-05-05
CN100366251C (zh) 2008-02-06
WO2003017990A3 (en) 2003-08-28
RU2313344C2 (ru) 2007-12-27
ZA200400772B (en) 2004-10-11
PT1420787E (pt) 2010-03-01
EP1420787B8 (en) 2010-09-01
BR0211972A (pt) 2004-09-21
US20030050255A1 (en) 2003-03-13
PL208685B1 (pl) 2011-05-31
CN1545414A (zh) 2004-11-10
CO5560568A2 (es) 2005-09-30
TWI324925B (en) 2010-05-21
ES2337130T3 (es) 2010-04-21
WO2003017990A2 (en) 2003-03-06
KR20040030157A (ko) 2004-04-08
EP1420787A2 (en) 2004-05-26
HUP0402396A2 (hu) 2005-09-28
PL367459A1 (en) 2005-02-21
DE60234840D1 (de) 2010-02-04
MXPA04001646A (es) 2004-05-31
KR20100089108A (ko) 2010-08-11
ECSP044981A (es) 2004-04-28
CA2457034C (en) 2010-07-27
NZ531224A (en) 2005-09-30
NO20040775L (no) 2004-02-17
HUP0402396A3 (en) 2005-12-28
MY157377A (en) 2016-06-15
RU2004108463A (ru) 2005-05-10
AU2002331172B2 (en) 2005-12-01
ATE452638T1 (de) 2010-01-15
JP2005501105A (ja) 2005-01-13
HK1065961A1 (en) 2005-03-11

Similar Documents

Publication Publication Date Title
PE20030311A1 (es) Composicion oftalmica que comprende ascomicina
BR0314266A (pt) Dispositivos e métodos para a melhora de visão
WO2007104541A3 (en) Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
BRPI0410784A (pt) métodos e composições para tratar distúrbios oculares
TNSN06071A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
TW200633709A (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions
CA2507375A1 (en) Use of rimexolone in the treatment of dry eye
DE69906030D1 (de) Linsen zur korrektur von kurzsichtigkeit
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
ATE433850T1 (de) Ophtalmische linsen und zusammensetzungen und verfahren zu deren herstellung
BR0213738A (pt) proteìnas morfogênicas ósseas (bmp), receptores de bmp e proteìnas de ligação de bmp e seu uso no diagnóstico e no tratamento de glaucoma
ATE196507T1 (de) Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
BRPI0512949A (pt) soluções para lentes oftálmicas contendo pelo menos um componente contendo silicone
ATE413179T1 (de) Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
MX2025000595A (es) Compuestos de heteroarilo como degradadores de cinasa 4 asociada al receptor de interleucina 1 (irak4) dirigidos por ligando
CA2254682A1 (en) Method of treating eye infections with azithromycin
JPS5977411A (ja) 酸素透過性ハ−ドコンタクトレンズ
ES2134268T3 (es) Anillo corneo intraestromal corrector del astigmatismo.
ATE464910T1 (de) Humane cd80-mutante und zusammensetzungen und methoden zu deren herstellung und verwendung
BR0110786A (pt) Composição aperfeiçoada de borracha
ES2126806T3 (es) Fibras conjugadas con alta capacidad de rizado y telas no tejidas fabricadas a partir de ellas.
EP1401496A4 (en) COMPOSITIONS AND METHODS FOR TREATING HYPERIMMUNE REACTIONS IN THE EYE
GR3033495T3 (en) Method for reducing tackniness of soft acrylic polymers.
BR0016415A (pt) Inibidores de adenosina cinase para o tratamento de dano retinal e de nervo ótico

Legal Events

Date Code Title Description
FC Refusal